Clinical Trials Logo

Chronic Hepatitis c Genotype 1 clinical trials

View clinical trials related to Chronic Hepatitis c Genotype 1.

Filter by:
  • None
  • Page 1

NCT ID: NCT04246723 Completed - Clinical trials for Chronic Hepatitis c Genotype 1

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Start date: May 6, 2019
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.

NCT ID: NCT01425203 Completed - Clinical trials for Chronic Hepatitis C Genotype 1

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Start date: November 23, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Boceprevir (BOC, SCH 503034, MK-3034) in combination with Peginterferon Alfa 2-b (PEG) plus Ribavirin (RBV) [PEG+RBV=PR] is effective in the treatment of chronic hepatitis C (CHC) genotype 1 among the Russian population. The primary hypothesis is that the percentage of participants achieving sustained virologic response in the BOC + PR group is superior to that in the Placebo (PBO) + PR group.

NCT ID: NCT00910975 Completed - Clinical trials for Chronic Hepatitis C, Genotype 1

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

TTG1
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate if the duration of treatment of hepatitis C with pegylated interferon and ribavirin can be individualized on the basis of how fast the hepatitis C virus concentration in the blood decreases, and if this is more cost-efficient than standard treatment.